MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
MacroGenics, a biopharmaceutical company focused on innovative antibody-based cancer therapies, will present at the 41st Annual J.P.
Rhea-AI Summary
MacroGenics, a biopharmaceutical company focused on innovative antibody-based cancer therapies, will present at the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & CEO, will deliver a business update on January 12, 2023, at 9:45 am PT / 12:45 pm ET. The presentation can be accessed via a webcast on MacroGenics' Investor Relations webpage, with an archived replay available for 30 days. MacroGenics leverages proprietary antibody technology platforms to develop its pipeline and establish strategic collaborations.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MGNX
The recorded move for MGNX in the trading session of this news was -6.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & Chief Executive Officer of MacroGenics, will provide a business update on Thursday, January 12, 2023, at 9:45 am PT / 12:45 pm ET.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.